Group 1 - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - The early trading volume in Hong Kong stocks reached 160.2 billion HKD [1] Group 2 - New pharmaceutical stocks in the Hong Kong Stock Connect saw significant gains, with ZhiJie AnKang-B (02617) surging over 49%, reaching a market capitalization of over 240 billion HKD; BaiZe Medical (02609) rose over 76%; and TongYuanKang Pharmaceutical-B (02410) increased by over 36% [1] - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at 1.35 HKD, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company well-prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose over 6% as its "SoFast" service officially launched in Macau, with Daiwa optimistic about the company's revenue growth prospects [2] - Valiant Bio-B (09887) increased by over 13%, with its core product LBL-024 for melanoma completing its first patient dosing in trials [2] - Bilibili-W (09626) rose by 2.78%, accumulating a total increase of about 25% over the past six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - LionTeng Holdings (02562) surged over 7% as it plans to acquire leading companies in artificial intelligence and blockchain to expand its digital finance layout [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted placement to raise approximately 5.392 billion HKD for structural adjustments in polysilicon capacity [2] - China General Nuclear Power Corporation Mining (01164) increased by 6.7%, as the U.S. seeks to expand its strategic uranium reserves, with institutions expecting a recovery in uranium prices [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted placement to raise about 1.15 billion HKD [2]

Market Overview - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - Early trading volume in Hong Kong stocks reached HKD 160.2 billion [1] Notable Stock Movements - New pharmaceutical stocks in the Hong Kong Stock Connect surged, with Yaojie Ankang-B (02617) rising over 49%, reaching a market capitalization of over HKD 240 billion [1] - Baize Medical (02609) saw an increase of over 76% [1] - Tongyuan Kang Pharmaceutical-B (02410) rose by over 36% [1] Specific Company Highlights - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at HKD 1.35, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose by over 6% as its "SoFast" service launched in Macau, with positive revenue growth prospects according to Daiwa [2] - Valiant Pharmaceuticals-B (09887) increased by over 13%, completing the first medication trial for its core product LBL-024 for melanoma [2] - Bilibili-W (09626) rose by 2.78%, accumulating a 25% increase over six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - Liontech Holdings (02562) surged over 7% as it plans to acquire a leading AI and blockchain company to expand its digital finance footprint [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted share placement to raise approximately HKD 5.392 billion for structural adjustments in polysilicon capacity [2] - CGN Mining (01164) increased by 6.7% amid expectations of rising uranium prices as the U.S. seeks to expand its strategic uranium reserves [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted share placement to raise about HKD 1.15 billion [2]

Core Viewpoint - The stock of Fosen Pharmaceutical in Hong Kong experienced significant volatility, with a peak increase of 400% during trading, ultimately settling at a 350% rise to HKD 1.53 [1] Group 1 - Fosen Pharmaceutical's stock surged dramatically, indicating strong market interest or potential news driving the price [1] - The stock's performance reflects a high level of trading activity, suggesting investor speculation or reaction to recent developments [1]

Core Viewpoint - Fosen Pharmaceutical (01652) experienced a significant stock price surge, rising over 410% at one point and currently up 350%, trading at HKD 1.53 with a transaction volume of HKD 13.89 million [1] Group 1: Company Developments - Fosen Pharmaceutical announced that its research and development product, "Metformin and Empagliflozin Tablets (I)", has received approval from the National Medical Products Administration of China [1] - The approved indication for the product is for the treatment of adult patients with type 2 diabetes who are currently receiving Empagliflozin and Metformin hydrochloride, aimed at improving blood glucose control in these patients [1] - The board believes that Metformin and Empagliflozin Tablets (I) is an important addition to the company's product pipeline in the diabetes treatment sector, providing more treatment options for diabetes patients [1]

Core Viewpoint - Fosen Pharmaceutical (01652) experienced a significant stock price surge, rising over 410% at one point and currently up 350% to HKD 1.53, with a trading volume of HKD 13.89 million [1] Group 1: Product Approval - Fosen Pharmaceutical announced that its research and development product, Metformin and Empagliflozin Tablets (I), has received approval from the National Medical Products Administration of China [1] - The product is indicated for the treatment of adult patients with type 2 diabetes who are currently receiving Empagliflozin and Metformin Hydrochloride, aimed at improving blood glucose control in these patients [1] - The board believes that Metformin and Empagliflozin Tablets (I) is an important addition to the company's product pipeline in the diabetes treatment sector [1] Group 2: Market Impact - The approval of this product is expected to provide more treatment options for a large number of diabetes patients [1]

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its Metformin and Empagliflozin Tablets (I), aimed at improving blood sugar control in adult patients with type 2 diabetes [1][2]. Group 1: Product Details - The Metformin and Empagliflozin Tablets (I) are a combination formulation of Metformin hydrochloride and Empagliflozin, which work synergistically to enhance glucose control compared to standard monotherapy [1]. - Metformin reduces hepatic glucose production, inhibits intestinal glucose absorption, and increases peripheral glucose uptake, thereby improving insulin sensitivity [1]. - Empagliflozin, an SGLT2 inhibitor, decreases renal glucose reabsorption, lowers renal glucose threshold, and promotes glucose excretion through urine [1]. Group 2: Market Context - The National Health Commission of China has set a target for 2025, aiming for a 70% management rate and knowledge awareness rate among diabetes patients, indicating a growing demand for diabetes medications [2]. - The Metformin and Empagliflozin Tablets (I) are classified as a Category B drug under medical insurance, offering advantages such as effective glucose-lowering effects and good patient tolerance without serious adverse reactions [2]. - Bioequivalence studies have shown that the product is consistent with the reference formulation, supporting its efficacy in improving blood sugar control in adult patients with type 2 diabetes [2]. Group 3: Strategic Importance - The company views the Metformin and Empagliflozin Tablets (I) as a significant addition to its product pipeline in the diabetes treatment sector, providing more treatment options for patients [2].

Core Viewpoint - Fosun Pharma (01652) has received approval from the National Medical Products Administration of China for its compound formulation "Metformin and Ertugliflozin Tablets (I)", aimed at improving blood sugar control in adult patients with type 2 diabetes who are already on metformin and ertugliflozin treatment [1] Group 1: Product Details - "Metformin and Ertugliflozin Tablets (I)" is a combination of metformin hydrochloride and ertugliflozin, which works synergistically to provide better glycemic control compared to standard monotherapy [1] - Metformin reduces hepatic glucose production, inhibits intestinal glucose absorption, and increases peripheral glucose uptake and utilization, thereby enhancing insulin sensitivity [1] - Ertugliflozin, an SGLT2 inhibitor, lowers renal glucose reabsorption, decreases renal glucose threshold, and promotes glucose excretion through urine [1] Group 2: Market Implications - The approval of this product is seen as a significant addition to Fosun Pharma's product pipeline in the diabetes treatment sector, providing more treatment options for diabetes patients [1]

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its "Metformin Empagliflozin Tablets (I)", which is intended for the treatment of type 2 diabetes in adults, enhancing blood sugar control in patients already on metformin and empagliflozin therapy [1] Company Summary - The "Metformin Empagliflozin Tablets (I)" is a combination formulation of metformin and empagliflozin, which works synergistically to improve glycemic control compared to standard monotherapy [1] - The company views this product as a significant addition to its diabetes treatment portfolio, providing more options for patients suffering from diabetes [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 自願公告 「二甲雙胍恩格列淨片(I)」獲批上市 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣佈，本集團研發的「二甲雙胍恩格列淨片(I)」，上市申請已獲得中國國家藥 品監督管理局批准，批准用於以下疾病的治療：本品配合飲食控制和運動，適用 於 正 在 接 受恩 格 列 淨 和 鹽 酸 二 甲 雙胍 治 療 的 2 型 糖 尿 病 成 人 患 者 ， 用於 改 善 這 些 患者的血糖控制。 「二甲雙胍恩格列淨片(I)」為鹽酸二甲雙胍、恩格列淨組成的複方製劑。藥理作用 如下：二甲雙胍可減少肝糖生成，抑制葡萄糖的腸道吸收，並增加外周組織對葡 萄糖 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 739,301,000 | | 0 | | 739,301,000 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 739,301,000 | | 0 | | 739,301,000 | 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港 ...